Drugs in Dev. Endocrinology
Phase III
United Kingdom 
Lead Product(s) : Baxdrostat
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy & Safety of Baxdrostat in Patients with Primary Aldosteronism
Details : Baxdrostat is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Hyperaldosteronism.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2025
Lead Product(s) : Baxdrostat
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eneboparatide Meets Primary Endpoint in CALYPSO Phase 3 for Hypoparathyroidism
Details : AZP-3601 (neboparatide) is a peptide agonist of the PTH1 receptor. Currently, being evaluated for the treatment of Chronic Hypoparathyroidism.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydrocortisone
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Eton Pharmaceuticals
Deal Size : $7.5 million
Deal Type : Licensing Agreement
Details : The acquisition advanced Eton’s leadership in pediatric rare diseases products providing a $100 million market opportunity.
Product Name : Alkindi Sprinkle
Product Type : Steroid
Upfront Cash : $3.5 million
March 27, 2020
Lead Product(s) : Hydrocortisone
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Eton Pharmaceuticals
Deal Size : $7.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 31, 2018
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2017
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Albiglutide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 10, 2017
Lead Product(s) : Albiglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Parexel | Q2 Solutions | PRA Health Sciences | Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2016
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Parexel | Q2 Solutions | PRA Health Sciences | Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Albiglutide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 17, 2016
Lead Product(s) : Albiglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 12, 2016
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2015
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
